NIKKEI 225
39,671.77 +498.62 (+1.27%) HANG SENG
18,137.34 +64.44 (+0.36%) CRUDE OIL
81.30 +0.47 (+0.58%) GOLD FUTURES
2,328.50 -2.30 (-0.10%) DOW
39,112.16 -299.05 (-0.76%) Bitcoin GBP
48,591.66 +234.27 (+0.48%)
REGN Jul 2024 1060.000 call
| Previous close | 28.55 |
| Open | 29.06 |
| Bid | 26.00 |
| Ask | 32.70 |
| Strike | 1,060.00 |
| Expiry date | 2024-07-19 |
| Day's range | 28.45 - 36.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 27 |
Simply Wall St.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 45% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,936 based on 2 Stage Free Cash Flow to...
ZacksRegeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
GlobeNewswireUpdated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
